Endicott JA - Search Results

1

FragLites-Minimal, Halogenated Fragments Displaying Pharmacophore Doublets. An Efficient Approach to Druggability Assessment and Hit Generation.

Wood DJ, Lopez-Fernandez JD, Knight LE, Al-Khawaldeh I, Gai C, Lin S, Martin MP, Miller DC, Cano C, Endicott JA, Hardcastle IR, Noble MEM, Waring MJ. Wood DJ, et al. Among authors: endicott ja. J Med Chem. 2019 Apr 11;62(7):3741-3752. doi: 10.1021/acs.jmedchem.9b00304. Epub 2019 Mar 26. J Med Chem. 2019. PMID: 30860382

2

Structural principles in cell-cycle control: beyond the CDKs.

Endicott JA, Noble ME. Endicott JA, et al. Structure. 1998 May 15;6(5):535-41. doi: 10.1016/s0969-2126(98)00055-0. Structure. 1998. PMID: 9634691 Free article. Review.

3

Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity.

Brown NR, Noble ME, Lawrie AM, Morris MC, Tunnah P, Divita G, Johnson LN, Endicott JA. Brown NR, et al. Among authors: endicott ja. J Biol Chem. 1999 Mar 26;274(13):8746-56. doi: 10.1074/jbc.274.13.8746. J Biol Chem. 1999. PMID: 10085115 Free article.

4

Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies.

Noble ME, Endicott JA. Noble ME, et al. Among authors: endicott ja. Pharmacol Ther. 1999 May-Jun;82(2-3):269-78. doi: 10.1016/s0163-7258(98)00051-5. Pharmacol Ther. 1999. PMID: 10454204 Review.

5

The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases.

Brown NR, Noble ME, Endicott JA, Johnson LN. Brown NR, et al. Among authors: endicott ja. Nat Cell Biol. 1999 Nov;1(7):438-43. doi: 10.1038/15674. Nat Cell Biol. 1999. PMID: 10559988

6

Cyclin-dependent kinases: inhibition and substrate recognition.

Endicott JA, Noble ME, Tucker JA. Endicott JA, et al. Curr Opin Struct Biol. 1999 Dec;9(6):738-44. doi: 10.1016/s0959-440x(99)00038-x. Curr Opin Struct Biol. 1999. PMID: 10607671 Review.

7

Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex.

Legraverend M, Tunnah P, Noble M, Ducrot P, Ludwig O, Grierson DS, Leost M, Meijer L, Endicott J. Legraverend M, et al. J Med Chem. 2000 Apr 6;43(7):1282-92. doi: 10.1021/jm9911130. J Med Chem. 2000. PMID: 10753466

8

Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.

Arris CE, Boyle FT, Calvert AH, Curtin NJ, Endicott JA, Garman EF, Gibson AE, Golding BT, Grant S, Griffin RJ, Jewsbury P, Johnson LN, Lawrie AM, Newell DR, Noble ME, Sausville EA, Schultz R, Yu W. Arris CE, et al. Among authors: endicott ja. J Med Chem. 2000 Jul 27;43(15):2797-804. doi: 10.1021/jm990628o. J Med Chem. 2000. PMID: 10956187

9

Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate.

Davies TG, Tunnah P, Meijer L, Marko D, Eisenbrand G, Endicott JA, Noble ME. Davies TG, et al. Among authors: endicott ja. Structure. 2001 May 9;9(5):389-97. doi: 10.1016/s0969-2126(01)00598-6. Structure. 2001. PMID: 11377199 Free article.

10

Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives.

Gibson AE, Arris CE, Bentley J, Boyle FT, Curtin NJ, Davies TG, Endicott JA, Golding BT, Grant S, Griffin RJ, Jewsbury P, Johnson LN, Mesguiche V, Newell DR, Noble ME, Tucker JA, Whitfield HJ. Gibson AE, et al. Among authors: endicott ja. J Med Chem. 2002 Aug 1;45(16):3381-93. doi: 10.1021/jm020056z. J Med Chem. 2002. PMID: 12139449

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

102 results

Search Page